

Erratum

STAC3 as a poor prognostic biomarker in renal clear cell carcinoma: relationship with immune infiltration: Am J Cancer Res. 2024; 14(7): 3294-3316

Yingnan Zhang*, Jingtao Li*, Luwen Feng*, Yue Cheng, Linlin Shi, Qian Yang, Zhaoyang Wang, Xuan Yi, Guocai Zhong, Xueying Sun, Zhifeng Cheng, Min Guo

The Fourth Affiliated Hospital of Harbin Medical University, Harbin 150001, Heilongjiang, China. *Equal contributors.

Received December 17, 2025; Accepted January 24, 2026; Epub January 25, 2026; Published January 30, 2026

During an internal review conducted by the author team, we identified several issues related to figure labeling and assembly. In **Figure 7**, the vertical axis labeling in certain panels was found to be inaccurate, and a scale bar has been added for improved clarity. Additionally, certain panels in **Figure 7E** and **7I** were misassembled during figure preparation. In **Figure 8E**, the labeling of STAC3 expression was corrected. Furthermore, the CD80 expression image for the “769-P conditioned medium-treated THP1” group was found to be duplicated during figure assembly. The study flowchart has been revised accordingly. These correc-

tions pertain solely to figure presentation and labeling and do not affect the underlying data, results, or conclusions of the study. We sincerely apologize for any errors and any inconvenience caused. The corrected **Figures 1, 7** and **8** are shown below.

Address correspondence to: Min Guo and Zhifeng Cheng, The Fourth Affiliated Hospital of Harbin Medical University, Harbin 150001, Heilongjiang, China. E-mail: 100886@hrbmu.edu.cn (MG); 002537@hrbmu.edu.cn (ZFC)

STAC3: a prognostic biomarker in renal clear cell carcinoma

Flowchart of this study






Figure 1. Flowchart of this study.

STAC3: a prognostic biomarker in renal clear cell carcinoma



STAC3: a prognostic biomarker in renal clear cell carcinoma

Figure 7. STAC3 modulates tumorigenic behaviors in KIRC cells. A, B: STAC3 knockdown in KIRC cells (769-P, Caki-1); C: Sh-STAC3 impairs KIRC cell proliferation over 24, 48, and 72 hours; D: Intracellular calcium ion concentration was down-regulated after Sh-STAC3; E, F: Sh-STAC3 inhibits KIRC cell migration at 24 and 48 hours; G, H: Sh-STAC3 inhibits KIRC cell invasiveness at 36 hours; I, J: Sh-STAC3 decreases KIRC cell proliferation. *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001.



STAC3: a prognostic biomarker in renal clear cell carcinoma

Figure 8. STAC3 expression in KIRC tissues correlates with macrophage infiltration and impacts prognosis. A, B: Higher expression of STAC3 in tumor tissues compared to adjacent non-tumor tissues; C: Patients with higher STAC3 expression exhibit worse prognosis in clinical samples; D, E: Differential expression of STAC3 in KIRC tissues affects the expression of CD68, CD80, and CD163; F, G: Expression of incoming and outgoing signaling pathways and intercellular signaling communication in different cells; H: Co-culture of tumor cells-CM with macrophages and expression of sh-STAC3-macrophage associated proteins (STAC3, CD68, CD80, CD163). *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001.